NCMD Seminar 6th March 2026
NCMD Seminar 6th March 2026
Talk 1: Analysing the representation of underserved groups in the CaPE clinic: a CNTW research service.
Harry Hackett, CaPE Clinic (CNTW) Harry Hackett is a higher research assistant working within the CNTW’s Care Pathway Enhancement (CaPE) Clinic. Harry also works as a central research assistant on the ASCEnD Trial.
Lauren Wall, Research Assistant (CNTW) Lauren Wall is a research assistant working on RELMED and the ASCEnD study being ran by CNTW.
The Care Pathway Enhancement (CaPE) clinic is a mood disorder research service within CNTW, funded by the NIHR Mental Health Translational Research Collaboration Mood Disorders workstream. The CaPE clinic provides a clinical framework for patients who do not meet the threshold for secondary care and offers research-informed assessments to identify those who may be suitable for research. This presentation shares findings from an analysis of CaPE referral data from being established in February 2022 until January 2026, focusing on under-served groups.
Talk 2: Small Effects, Big Impact? Comparing and Rethinking Outcomes in Vagus Nerve Stimulation for Depression and Epilepsy
Dr Matthew Pitson, Trust Grade Doctor, Care Pathway Enhancement Clinic (CNTW)Dr Matthew Pitson is a doctor working at the Care Pathway
Enhancement Clinic, following completion of his Foundation Training in the Northeast of England. He is involved in a range of clinical trials focused on difficult-to-treat mood disorders, with a particular academic interest in neuromodulation. His current research work explores how emerging treatments, including vagus nerve stimulation, can be evaluated through multidimensional measures of recovery such as symptoms, functioning, and quality of
life.
Dr Jaume Clemente-Calvo, Honorary Trust Grade Doctor (CNTW) Jaume Clemente-Calvo is a final-year Spanish psychiatry trainee (ST4 equivalent) who has spent the past four months undertaking a clinical attachment at the CAPE/RADS Clinic in 缅北禁地, UK. His academic interests centre on neuroimaging and the affective dimensions of first-episode psychosis.
This seminar explores how vagus nerve stimulation (VNS) produces clinical benefits across difficult-to-treat depression and epilepsy, with a focus on quality-of-life outcomes and multidimensional recovery. Drawing on a narrative review and quantitative effect-size analysis, the talk compares how therapeutic benefit is measured across both neurological and psychiatric conditions, highlighting how traditional symptom-based metrics may underestimate meaningful change in depression.